Andreas Rost
Impact in
- Oncology top 2%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 7
- Colorectal Cancer Treatments and Studies 6
- Cancer Treatment and Pharmacology 2
-
- Lymphoma Diagnosis and Treatment 3
- Co-authors
- Mathias Rummel (3 shared papers)Paris Sophokles Mitrou (2 shared papers)Horst Neuhaus (1 shared paper)Michael Neise (2 shared papers)Ralf Wilkowski (1 shared paper)Wolfgang Gesierich (1 shared paper)Andreas Schalhorn (1 shared paper)Volker Heinemann (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Annals of Oncology (1 paper)International Journal of Cancer (1 paper)BMC Cancer (1 paper)European Journal of Cancer (1 paper)
- Partner nations
- GermanySwitzerland
In The Last Decade
Andreas Rost
15 papers receiving 2.6k citations
Andreas Rost's Hit Papers
Peers
Comparison fields: 5 of 79
- Oncology 1.8k
- Hepatology 288
- Pathology and Forensic Medicine 615
- Genetics 264
- Cancer Research 334
Countries citing papers authored by Andreas Rost
This map shows the geographic impact of Andreas Rost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Rost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Rost more than expected).
Fields of papers citing papers by Andreas Rost
This network shows the impact of papers produced by Andreas Rost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Rost. The network helps show where Andreas Rost may publish in the future.
Co-authors
The 25 scholars most cited alongside Andreas Rost, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 1433 |
| 2 | 2006 | 579 | |
| 3 | 2005 | 367 | |
| 4 | 2004 | 165 | |
| 5 | 2002 | 84 | |
| 6 | 2010 | 42 | |
| 7 | 2001 | 13 | |
| 8 | 2017 | 12 | |
| 9 | 2000 | 9 | |
| 10 | 2005 | 7 | |
| 11 | [Further animal experiments on the anti-inflammatory action of hostacain]. | 1967 | 2 |
| 12 | 1999 | 2 | |
| 13 | [Animal experiments for the study of the antiphlogistic action of hostacain and oxyprocaine forte]. | 1967 | 2 |
| 14 | 1998 | 1 | |
| 15 | 1998 | 1 | |
| 16 | 2000 | 0 |
About Andreas Rost
Andreas Rost is a scholar working on Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Hepatology and Genetics, having authored 16 papers that have together received 2.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (6 papers), Lymphoma Diagnosis and Treatment (3 papers), Gastric Cancer Management and Outcomes (2 papers), Cancer Treatment and Pharmacology (2 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Nanoparticle-Based Drug Delivery (1 paper), Hepatocellular Carcinoma Treatment and Prognosis (1 paper) and Advanced Breast Cancer Therapies (1 paper). The work is most often cited by research in Oncology (1.8k citations), Hepatology (288 citations), Pathology and Forensic Medicine (615 citations), Genetics (264 citations) and Cancer Research (334 citations). Andreas Rost has collaborated with scholars based in Germany and Switzerland. Frequent co-authors include Mathias Rummel, Paris Sophokles Mitrou, Horst Neuhaus, Michael Neise, Ralf Wilkowski, Wolfgang Gesierich, Andreas Schalhorn, Volker Heinemann, Ursula Vehling‐Kaiser and H Schönekäs. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Cancer, BMC Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.